Prevention and treatments for adverse drug reactions of oral small molecular targeting drugs
chen zhe1; 3; mei dan2; tang zhi-qiang3(1 peking union medical college; beijing 100730; china; 2 department of pharmacy; peking union medical college hospital; beijing 100730; china; 3 department of pharmacy; cancer institute &hospital; chinese academy of medical sciences; beijing 100021; china)

..............page:1807-1811,1816

Progress in research of multi-kinase inhibitors for treatment of hepatocellular carcinoma
gong xin-lei; qin shu-kui(medical oncology department of the pla cancer center; the bayi hospital; nanjing 210002; china)

..............page:1713-1722

Clinical studies on new anticancer drugs during the past 5 decades in China
sun yan(cancer hospital; cams & pumc; beijing 100021; china)

..............page:1695-1700

Effect of ethaselen on the content and activity of liver CYP450 enzyme in H-22 tumor bearing mice
yin jin; yin han; ren xiao-yuan; xu jing; zeng hui-hui(state key laboratory of natural and biomimetic drugs; beijing 100191; china)

..............page:1783-1786,1797

Efficacy of endostar combined with vinorelbine and cisplatin in treatment of advanced non-small-cell lung cancer
sun hong-ya1; chen jun2(yinzhou peoples hospital; 1 department of pharmacy; 2 department of radiochemotherapy; ningbo 315040; china)

..............page:1764-1766

di si jie xin yi miao xin xi bao guo ji yan tao hui tong zhi

..............page:1763

Advance in pharmacology and clinical research of S-1 in the treatment of gastric cancer
li xu; zhao yun-bo(department of medical oncology; beijing hospital; ministry of health; beijing 100730; china)

..............page:1723-1727

sang guo wei dang xuan zhong guo yi yao gong ye ke yan kai fa cu jin hui xin yi ren hui chang

..............page:1817

Advances in the inhibitors of FLT-3 receptor tyrosine kinase
ma xiang-jun; fang zheng; chen yan; wei ping(college of life science and pharmaceutical engineering; nanjing university of technology; nanjing 210009; china)

..............page:1734-1738

zhong guo yao li xue hui di shi ci quan guo xue shu hui yi di yi lun tong zhi

..............page:1722

Progress in targeted therapeutic agents for renal cell carcinoma
zhu yi ; fu de-xing(department of pharmacy; beijing hospital; beijing 100730; china)

..............page:1728-1733

A new in vitro tumor chemosensitivity assay based on tissue culture
liang yong-ju; fu li-wu (state key laboratory of oncology in southern china; cancer center; sun yat-sen university; guangzhou 510060; china)

..............page:1793-1797

Efficacy of oxycodone-acetominophen by different administrations in controlling moderate to severe cancer pain and break-out pain
pang jie1; jie bao-juan2; li yan-ping1(1 department of anesthesiology; beijing friendship hospital affiliated to the capital medical universitybeijing 100050; china; 2 department of anesthesiology; china rehabilitation research center; beijing 100068; china)

..............page:1767-1770,1776

Evaluation on clinical application of 3 novel antineoplastic antibodies
chen qian-chao1; liu tao1; li zhi-ming2; pan ying1; huang hong-bing1(1 department of pharmacy; 2 department of internal medicine; state key laboratory of oncology in south china; tumor hospital affiliated to sun yat-sen university; guangzhou 510060; china)

..............page:1798-1802,1806

Phase I clinical tolerance study of chidamide(CS055) in patients with advanced cancer
dong mei; xing pu-yuan; shi yuan-kai; feng feng-yi (department of medical oncology; cancer institute & hospital; chinese academy of medical science & peking union medical college; beijing 100021; china )

..............page:1745-1750

sang guo wei chu xi zhong guo kang sheng su 60 nian gao feng lun tan

..............page:1817

guan yu ju ban 2009 nian yi yao ti zhi gai ge - ji yu he tiao zhan guo ji gao feng lun tan de yu tong zhi

..............page:1700

Clinical pharmacists' practice in bone tumor ward
zhang wei; zhen jian-cun; zhang qing; zhang xiao-lin(beijing jishuitan hospital; beijing 100035; china)

..............page:1803-1806

CMC review of veregen and its enlightenment to the quality control of new Chinese herbal medicine
zhou yue-hua ; han wei(center for drug evaluation; state food and drug administration; beijing 100038; china)

..............page:1705-1708

Quality control study of chiral drugs
li xue-mei; huang xiao-long(center for drug evaluation; state food and drug administration; beijing 100038; china)

..............page:1709-1712,1738

Impaired liver function induced by sorafenib in the patient with liver transplantation(a case report)
yu xian-huan1; liu chao1; zeng yun-jie2; wang jie1(1 department of hepato-pancreato-biliary surgery; 2 department of pathology; sun yat-sen memorial hospital; sun yat-sen university; guangzhou 510120; china)

..............page:1812-1814

Study on enrichment and purification of astragaloside Ⅳ and total saponin with D101 macroreticular resin in Shengqi Fuzheng freeze-drying preparation for injection
yang hao1; zhao yi-lei2; tang xing1(1 school of pharmacy; shenyang pharmaceutical university; shenyang 110016; china; 2 department of pharmacy; first clinical college of harbin medical university; harbin 150010; china)

..............page:1771-1776

Bicalutamide in the treatment of advanced prostate cancer:a 52 case report
zhang jian-ping; lin zong-ming; liu yu-jun; zhang li; wang guo-ming(department of urology; zhongshan hospital; fudan university; shanghai 200032; china)

..............page:1757-1759

osi pharmaceuticals gong si fa xian rong liu ji osi-906

..............page:1750

Difference of mitotic cell death induced by lidamycin in human hepatoma cells and normal liver cells
yang a-jing; liang yue-xin; wang zhen; li dian-dong; he qi-yang(institute of medicinal biotechnology; peking union medical college &chinese academy of medical sciences; beijing 100050; china)

..............page:1777-1782

Mechanism of anticancer effect in vitro and in vivo of a novel anti-tumor protein from Meretrix Meretrix Linnaeus
zhang yu-yan1; 3; zhang sheng-hua2; ning xuan-xuan1; 3; wang cui-cui1; 3; liu ming1; lin xun-kun1(1 institute of oceanology; chinese academy of sciences; qingdao 266071; chin.; 2 institute of medicinal biotechnology; chinese academy of medical sciences and peking union medical college; beijing 100050; china.; 3 graduate school; chinese academy of sciences; beijing 100039; china)

..............page:1787-1792

lin chuang an quan he li yong yao an li fen xi 500 li zheng ding qi shi

..............page:1744

guan yu ju ban yao pin zhuan li zhan lue zhan shu ying yong yan tao hui de tong zhi

..............page:1814

di 13 jie shi jie fei ai da hui kuai xun

..............page:1689-1690

di shi er jie quan guo lin chuang zhong liu xue da hui zuo 2009 nian csco xue shu nian hui ji jiang zhao kai

..............page:1694

Efficacy of compound Kusheng injection in combination with chemotherapy in patients with advanced non-small cell lung cancer
duan-ping1; xiao min-wei1; xiao wen1; li ping2(1 department of oncology; the first people s hospital; chengdu 610041; china; 2 center of oncology; huaxi hospital; sichuan university; chengdu 610041; china)

..............page:1760-1763

A phase II clinical trial of morphine sulfate suppository in the treatment of cancer pain
chen hui-hua1; li shu-min2; zhang jin2; zhang lin2(1 wuhan hospital of traditional chinese medicine; wuhan 430014; china; 2 mayinglong pharmaceutical group co.; ltd; wuhan 430064; china)

..............page:1751-1756,1759

Pharmacology and clinical evaluation of icotinib hydrochloride
tan fen-lai1; zhang li2; zhao qiong3; liu dong-yang4; hu yun-yan1; liu yong1; ding lie-ming1; hu bei4; wang yin-xiang1(1 zhejiang beta pharma; hangzhou zhejiang 311100; china; 2 department of respiratory; peking union medical college hospital; beijing 100730; china; 3 department of respiratory; the first affiliated hospital of college of medicine; zhejiang university; hangzhou 310003; china ; 4 clinical pharmacology research center; peking union medical college hospital; beijing 100730; china )

..............page:1691-1694

Approach and strategy for the problems related to Chinese herb injections
lin hong-sheng ; zhang ying(department of oncology; guang anmen hospital; china academy of chinese medical sciences; beijing 100053; china)

..............page:1701-1704

A case of vision loss after the chemotherapy of cisplatin combined with paclitaxel
shen min; ling yun-hua; wu hong-bin(department of pharmacy; cancer hospital and department of oncology; shanghai medical college; fudan university; shanghai 200032; china)

..............page:1815-1816

Progress in research of Vinca alkaloids and its targeting prodrugs
zhang ai-hong1; 2; zhong bo-hua1(1 institute of pharmacology and toxicology; academy of military medical sciences; beijing 100850; china; 2 department of technology and practice to fulfilling chemical weapon convention; command and engineering institute of chemical defense; beijing 102205; china)

..............page:1739-1744